Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches
Open accessThe DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Abstract
Since its discovery in 2012, the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) system has supposed a promising panorama for developing novel and highly precise genome editing-based gene therapy (GT) alternatives, leading to overcoming the challenges associated with classical GT. Classical GT aims to deliver transgenes to the cells via their random integration in the genome or episomal persistence into the nucleus through lentivirus (LV) or adeno-associated virus (AAV), respectively. Although high transgene expression efficiency is achieved by using either LV or AAV, their nature can result in severe side effects in humans. For instance, an LV (NCT03852498)- and AAV9 (NCT05514249)-based GT clinical trials for treating X-linked adrenoleukodystrophy and Duchenne Muscular Dystrophy showed the development of myelodysplastic syndrome and patient’s death, respectively. In contrast with classical GT, the CRISPR/Cas9-based genome editing requires the homologous direct repair (HDR) machinery of the cells for inserting the transgene in specific regions of the genome. This sophisticated and well-regulated process is limited in the cell cycle of mammalian cells, and in turn, the nonhomologous end-joining (NHEJ) predominates. Consequently, seeking approaches to increase HDR efficiency over NHEJ is crucial. This manuscript comprehensively reviews the current alternatives for improving the HDR for CRISPR/Cas9-based GTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Major steps in non-homologous end joining (NHEJ) and Homology-directed repair (HDR). NHEJ is initiated by binding of Ku to the DSB ends. This is followed by recruiting DNA-PKcs and other necessary scaffolding factors that bring DSB ends together. Nucleases process the incompatible ends, polymerases fill gaps, and finally, the ends are ligated by DNA ligases. This process ultimately leads to the formation of INDELs. HDR is initiated by the binding of MRN that stabilizes DSB ends. Then, 5′ exonucleases produce short-range resections followed by long-range resections. The long 3′ overhangs are directed for homology search and strand invasion by RAD51, leading to D-loops’ formation. Finally, the exchanged DNA strands are resolved, leading to precise editing. Several platforms can be used as donor templates, including long single-stranded oligodeoxynucleotide (lssDNA), single-stranded oligodeoxynucleotide (ssODN), double-stranded oligodeoxynucleotide (dsODN), and double-stranded DNA (dsDNA) which can be carried through non-viral vectors, as well as DNA templates loaded into viral vectors. For more details related to donor templates and their impact on HDR, we strongly encourage readers to review the paper by Shakirova et al., 2023 [52]. Although differences in the recognition of ssDNA (i.e., BRCA1) and dsDNA (i.e., BRCA2) have been well-documented, in both scenarios, the homologous recombination takes place, leading to precise genome editing in the context of the CRISPR/Cas9 system. This figure was created with BioRender.com.](https://figures.cochat.ai/paper-figures/837092945ecf420e921b22471c115cf2/current-strategies-for-increasing-knock-in-efficiency-in-crispr-cas9-based-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, CRISPR-Cas9-mediated HDR frequently results in monoallelic knock-ins, where only one allele is precisely modified while the other remains unedited or acquires variable indels [5].”
From Rapid and Robust Generation of Homozygous Fluorescent Reporter Knock-In Cell Pools by CRISPR-Cas9 (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“Online predictors score sgRNA according to their on-target activity based on sophisticated studies published by Doench et al. (2016) [93].”
BackgroundDouble nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299 · cited 1×
“PAM-out configuration, together with off-sets between 40–70 bp and 50–70 bp when nCas9 (D10A) or nCas9 (H840A) are used, respectively, have demonstrated higher on-target cleavage efficiency [39], while decreasing between 50–1500-fold the Cas9 off-target events in comparison to wtCas9 [39,94].”
BackgroundThe molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants
Makarova, K. S., Wolf, Y. I., Iranzo, J., Shmakov, S. A., Alkhnbashi, O. S., Brouns, S. J. J., Charpentier, E., Cheng, D., Haft, D. H., Horvath, P., et al. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0299-x · Cited by 2,445
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414 · cited 1×
“Even though some efforts have been made to increase the Cas9 specificity without size changes resulting in several Cas9 variants (see Table 1), they have a marginal effect on the knock-in efficiency increase [26,27,33].”
BackgroundCRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029 · cited 6×
“The CRISPR/Cas9 comprises a sgRNA in combination with the Cas9 endonuclease, which interacts with the targeted DNA to mediate DSB [7].”
BackgroundInfluentialCRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962 · cited 1×
“By knocking out the BCL11A gene (80%), the authors found a significant increase in fetal hemoglobin synthesis [46].”
BackgroundNon-homologous DNA end joining and alternative pathways to double-strand break repair
Chang, H. H. Y., Pannunzio, N. R., Adachi, N., & Lieber, M. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.48 · Cited by 1,757
Cited by
Gene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Gene editing and CRISPR-dependent homology-mediated end joining
Ruis, B. L., Bielinsky, A., & Hendrickson, E. A. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01442-z · Cited by 26
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 25
Yan, B., Yan, C., Ding, Y., Cai, S., Wang, Y., Agbo, E., Xu, X., Qin, K., & Fu, Q. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1723885 · Cited by 12
Yu, C., Adavikolanu, R., Kaake, R. M., & Huang, L. (2025) · Mass Spectrometry Reviews · doi:10.1002/mas.21926 · Cited by 10
Metadata
- Authors
- Leal, A., Herreno-Pachón, A., Benincore-Flórez, E., Karunathilaka, A., & Tomatsu, S.
- Affiliations
- Pontificia Universidad Javeriana (CO)
- Nemours Children’s Health, Wilmington, DE 19803, USA
- Nemours Children's Health System (US)
- Thomas Jefferson University (US)
- Corresponding author
- Tomatsu, Shunji
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-02-20
- Volume
- 25
- Issue
- 5
- Pages
- 2456
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10931195
- OpenAlex
- W4391968889
- Cited by
- 58
- References
- 130
- Citations by year
- 2026: 23 · 2025: 29 · 2024: 6
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Medicine Forum (submittedVersion, cc-by)
- Funders
- A Cure for Robert, Inc. (1R01HD102545-01A1)
- Austrian MPS society (1R01HD102545-01A1)
- The Carol Ann Foundation (1R01HD102545-01A1)
- Angelo R. Cali and Mary V. Cali Family Foundation, Inc. (1R01HD102545-01A1)
- The Vain and Harry Fish Foundation, Inc. (1R01HD102545-01A1)
- The Bennett Foundation (1R01HD102545-01A1)
- Jacob Randall Foundation (1R01HD102545-01A1)
- Nemours Funds (1R01HD102545-01A1)
- Eunice Kennedy Shriver (1R01HD102545-01A1)
- National Institute of Child Health and Human Development of the National Institutes of Health (NICHD) (1R01HD102545-01A1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- CRISPR/Cas9, knock-in efficiency, homologous recombination, non-homologous end joining, genome editing, gene therapy, lentivirus, adeno-associated virus, X-linked adrenoleukodystrophy, Duchenne muscular dystrophy, myelodysplastic syndrome
- MeSH terms
- Gene Editing, Animals, Humans, Mammals, Genetic Therapy, DNA End-Joining Repair, Recombinational DNA Repair, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches. https://app.cochat.ai/papers/10.3390/ijms25052456
- The paper
- Leal, A., Herreno-Pachón, A., Benincore-Flórez, E., Karunathilaka, A., & Tomatsu, S. (2024). Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.